Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia

This episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, which took place in San Diego, CA. You will hear the latest updates in sickle cell disease (SCD), thalassemia, and hemophilia from leading experts.

First, Sophia Delicou, MD, Hippokration General Hospital, Athens, Greece, will provide an update on the HIBISCUS (NCT04624659) trial of etavopivat in SCD, and Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, will present updated results of the RUBY (NCT04853576) trial investigating reni-cel in severe SCD. This will be followed by an update of a trial being conducted in patients with transfusion-dependent thalassemia, the ENERGIZE-T study (NCT04770779), from Maria Domenica Cappellini, MD, University of Milan, Milan, Italy. Finally, you will hear the results of the explorer7 trial (NCT04083781) in hemophilia A and B from Amy Shapiro, MD, Indiana University Hemophilia Center, Indianapolis, IN.

The post Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia appeared first on VJHemOnc.